The road ahead for large pharma: long-term science and innovation

Drug Discovery Today

Volumn 14, Issue 9-10, 2009, Pages 439-441

  Lundberg, Jan M ^a   Reilly, Chris ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; HYPERTENSION; PATENT;

DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; ORGANIZATIONAL INNOVATION; SCIENCE;

EID: 67349156630     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.03.002     Document Type: Editorial

References (6)

1. B Zycker et al. (2008) The truth about drug innovation: thirty-five summary case histories on private sector contributors to pharmaceutical science. Center for Medical progress at the Manhattan University. Medical Progress Report, No 6 June 2008 (http://www.manhattan-institute.org/html/mpr_06.htm)
2. In-Pharma Technologist.com: "M&A fever sweeps drug industry in wake of Pfizer-Wyeth deal" (http://www.in-pharmatechnologist.com/Industry-Drivers/M-A-fever-sweeps-drug-industry-in-wake-of-Pfizer-Wyeth-deal)
3. Philadelphia Inquirer: "Experts: Wyeth pipeline not that attractive" (http://www.philly.com/philly/business/38520187.html)
4. R&D Directions (http://www.pharmalive.com/magazines/randd/ http://www.pharmalive.com/magazines/randd/view.cfm?articleid=6999&search=1 http://www.astrazeneca-us.com/careers/?itemId=4555175)
5. These statistics come from John Patterson's "Viewpoint" in Pharmaceutical Technology Magazine, "Can Big Pharma Produce the Next Generation of Medicines?", August 2, 2008
6. Impact report: Cost to develop new biotech products is estimated to average $1.2 billion, Tufts University, vol. 8, No 6, Nov/Dec 2008